STEP4NAMs

Step up the use for new approach methodologies to replace animal testing


See partners​

3,799,419.27 €
EU Funding
6,332,365.47 €
Total Budget
2025-2028
Timeline
Germany, Ireland, The Netherlands, France, Belgium & Luxembourg
Countries

Project summary


​New Approach Methodologies (NAMs) are advanced digital and biotechnological methods that enable the testing of drugs and medical devices without the use of animals. They offer great potential to improve healthcare and innovation across Europe.

While most North-West Europe (NWE) regions are ranked as strong health innovators (according to the Regional Innovation Scoreboard), the adoption of NAMs still faces several barriers. A 2023 report by ECHA identified the key challenges:

  • Lack of knowledge and awareness
  • Regulatory uncertainty
  • Limited funding opportunities
  • Fragmented infrastructure

These issues vary across STEP4NAMs regions:

  • Germany (DE): underfunded research and development
  • Netherlands (NL): lack of hospital and lobbying networks
  • France/Belgium (FR/BE): strong NAM ecosystems, but limited recognition
  • France (FR): many isolated initiatives, lacking coordination
  • Ireland (IE): strong UK ties hinder EU cooperation
  • Luxembourg (LU): limited industrial presence

The Solution: Cross-Border Collaboration

EU-wide efforts to promote NAMs exist, but are scattered and lack coordination, especially in the BioPharma and MedTech sectors. STEP4NAMs addresses this gap by uniting partners from six NWE countries (DE, NL, FR, BE, IE, LU), building on their regional strengths to promote transnational cooperation.

The project offers:

  • Access to well-established Life Sciences and MedTech networks in DE, NL, BE, and FR
  • Expertise in key NAM areas such as tissue engineering, digital twins, organoids, and 3D-printed models
  • Collaboration with pharma industry players, 3R (Replace, Reduce, Refine) networks, and complementary EU projects
  • Active participation in major events to disseminate results

A Holistic and Practical Approach

STEP4NAMs engages BioPharma and MedTech stakeholders throughout the NAM value chain, with a strong focus on SMEs as key drivers of innovation. The main project outcomes include:

  • A joint strategy and sector-specific action plans for NAM adoption
  • Four pilot studies to validate four NAMs
  • A comprehensive NAM Validation Manual
  • A training and support programme for 186 participants to demonstrate NAM effectiveness

By fostering acceptance and uptake of NAMs, STEP4NAMs will strengthen innovation capacity, increase resilience in the health sector, and reduce animal testing in NWE. 



Current highlights


STEP4NAMs has extended the application window and broadened eligibility for its on-site training in Tübingen, taking place in January. Applications are open until 29 November.
  • The training remains primarily aimed at employees of small and medium-sized enterprises (SMEs). PhD candidates employed by an SME are now also eligible to apply.
  • In addition, a small number of places are now open to staff at higher education institutions, research organisations and clinical institutions, excluding PhD candidates.
Please note: PhD candidates are eligible only if they are employed by an SME.

 Learn more

February 2025
Kickoff-Meeting

Stuttgart - Germany

September 2025
Partner-Meeting 2

Hertogenbosch - Netherlands

December 2025
Partner-Meeting 3

Strasbourg - France

March 2026
Partner-Meeting 4

Tübingen - Germany 

March 2026
Start of Training & Support Program
2028
Final project event

 

At a glance

All key information about the project can be found in this flyer.

View flyer

The latest project news

Your Dynamic Snippet will be displayed here... This message is displayed because you did not provided both a filter and a template to use.